21-hydroxylase deficiency classification: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {Congenital adrenal hyperplasia due to 21-hydroxylase deficiency}} {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}} ==Overview== ==Classification== '''Depending...")
 
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{Congenital adrenal hyperplasia due to 21-hydroxylase deficiency}}
{{Congenital adrenal hyperplasia due to 21-hydroxylase deficiency}}


{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}

Revision as of 15:21, 20 September 2012

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

21-hydroxylase deficiency classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 21-hydroxylase deficiency classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 21-hydroxylase deficiency classification

CDC on 21-hydroxylase deficiency classification

21-hydroxylase deficiency classification in the news

Blogs on 21-hydroxylase deficiency classification

Directions to Hospitals Treating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Risk calculators and risk factors for 21-hydroxylase deficiency classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Classification

Depending on severity:

  • Severe 21-hydroxylase deficiency causes salt-wasting CAH, with life-threatening vomiting and dehydration occurring within the first few weeks of life. Severe 21-hydroxylase deficiency is also the most common cause of ambiguous genitalia due to prenatal virilization of genetically female (XX) infants.
  • Moderate 21-hydroxylase deficiency is referred to as simple virilizing CAH; and typically is recognized as causing virilization of prepubertal children.
  • Still milder forms of 21-hydroxylase deficiency are referred to as non-classical CAH and can cause androgen effects and infertility in adolescent and adult women.

Depending on onset:

  • Early-onset: Severe 21-hydroxylase deficient CAH
  • Childhood onset (simple virilizing) CAH
  • Late onset (nonclassical) CAH

References


Template:WikiDoc Sources